Matthew A. Lunning, DO

Articles

Future Directions and Unmet Needs in Relapsed/Refractory MCL

February 20th 2024

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Sequencing Therapies in the Third-Line and Beyond Setting for MCL

February 13th 2024

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Current Treatment Options in Third-line MCL

February 13th 2024

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Current Treatment Options in Second-line MCL

February 6th 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

ASH 2023 Updates on Frontline Therapies in MCL

February 6th 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Current Treatment Options in First-Line MCL

January 30th 2024

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

Unmet Needs in Treating Relapsed/Refractory FL

January 30th 2024

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

January 23rd 2024

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Choosing CAR T-cells as Third-line and Beyond Therapy for FL

January 23rd 2024

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

January 16th 2024

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Zanubrutinib as Third-Line and Beyond Therapy for FL

January 16th 2024

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Tazemetostat as Third-line and Beyond Therapy for FL

January 10th 2024

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

January 10th 2024

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL

August 3rd 2022

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

Dr. Lunning on the Efficacy of Axi-Cel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

June 2nd 2021

Matthew Lunning, DO, discusses the efficacy of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Lunning on Initial Treatment Considerations in CLL

November 10th 2020

Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.

Dr. Lunning Discusses the Treatment of Peripheral T-Cell Lymphoma

July 23rd 2018

Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the treatment of patients with peripheral T-cell lymphoma.